about
Oral Manifestations and Molecular Basis of Oral Genodermatoses: A Review.Clinical genetic counselling for familial cancers requires reliable data on familial cancer risks and general action plans.Gastrointestinal tract cancers: Genetics, heritability and germ line mutationsBeliefs about the causes of breast and colorectal cancer among women in the general populationUse of an educational computer program before genetic counseling for breast cancer susceptibility: effects on duration and content of counseling sessions.Complementary analysis of microsatellite tumor profile and mismatch repair defects in colorectal carcinomas.Germline mutations in BMPR1A/ALK3 cause a subset of cases of juvenile polyposis syndrome and of Cowden and Bannayan-Riley-Ruvalcaba syndromes.Effect of a computer-based decision aid on knowledge, perceptions, and intentions about genetic testing for breast cancer susceptibility: a randomized controlled trial.Regular surveillance for Li-Fraumeni Syndrome: advice, adherence and perceived benefits.Bap1 is essential for kidney function and cooperates with Vhl in renal tumorigenesisSingle nucleotide variations: biological impact and theoretical interpretation.Etiopathogenesis and clinical presentation of carotid body tumors.Pre-test prediction models of BRCA1 or BRCA2 mutation in breast/ovarian families attending familial cancer clinics.Referral for cancer genetics consultation: a review and compilation of risk assessment criteriaThe diagnosis of CAD in women: addressing the unmet need - a report from the national expert roundtable meetingIdentification of a comprehensive spectrum of genetic factors for hereditary breast cancer in a Chinese population by next-generation sequencing.Delivery of Internet-based cancer genetic counselling services to patients' homes: a feasibility studyBioinformatics for cancer management in the post-genome era.Gene-expression profiling in differentiated thyroid cancer--a viable strategy for the practice of genomic medicine?Scoping the family history: assessment of Lynch syndrome (hereditary nonpolyposis colorectal cancer) in primary care settings--a primer for nurse practitioners.Potential of Advexin: a p53 gene-replacement therapy in Li-Fraumeni syndrome.Targeting lymphotoxin-mediated negative selection to prevent prostate cancer in mice with genetic predisposition.Re-overcoming barriers in translating biomarkers to clinical practice.Hereditary Factors in Esophageal Adenocarcinoma.Genetic discrimination in health insurance: current legal protections and industry practices.p53 Testing for Li-Fraumeni and Li-Fraumeni-like syndromes.A prospective biological study in relation to a family with Li-Fraumeni syndrome.Genetic and clinical investigation of pheochromocytoma: a 22-year experience, from Freiburg, Germany to international effort.The role of cognitive appraisal and worry in BRCA1/2 testing decisions among a clinic populationPresumption, privilege, and preemption
P2860
Q26738828-E5C5F8BD-6D96-4858-9528-A79100BB7C54Q30974845-90BA8479-6A72-4104-B5D6-3B1E43FEFC27Q33599436-90AF113F-6C27-4336-8C37-181E519924F6Q33604094-D1683CFC-D002-43C5-BDDA-D144518BCA2EQ33947420-3B1ACC72-9DEF-4CA5-8305-1876B4B39CE9Q34013017-219C7F08-1CE8-497E-9974-64363681B88BQ34020502-F077FA83-B063-464B-8CD0-D1AA0B4C0D07Q34049921-200D738E-981D-4840-8EB0-098549C6037EQ34306492-B045E2A2-7A2C-428B-9DA5-9B8A0F95D2B3Q34580977-145BA7F6-5AAF-4083-8D37-CC5690A83BB3Q34621290-98F6BF3C-3C25-4CD0-8053-F398EBD99111Q34972749-E74F297B-8F6A-4547-ABC9-91D38B58A557Q35443103-45F15435-31D8-4830-956F-238AC6ACD1BEQ35444793-209EF830-CFF2-4014-9A43-01DA19A5EB2EQ35540593-F6C0E72E-E391-43F0-B30F-AF4DA8BAF22EQ35558112-AB305080-1A32-4DCC-A6EE-947537C24F41Q35686808-6C32A72A-8D5D-4861-93C4-25B2EEEF1BE9Q36427239-E0F28434-CA3E-4F44-A781-C0425B6989FEQ36429534-8484CAB9-3B20-4289-9A23-E2961125F1B4Q37083675-4C364DA3-9BE9-4537-8482-98F46B2FB79AQ37351986-5EA1CF94-A271-42A8-8521-4E301D71FB09Q37385949-533BD0A5-8473-406F-863E-234533B0E742Q38088713-5057AC33-8C41-45AE-8982-FA3FAD44B518Q38671337-CF32D60D-88F0-4066-8E1B-8E682C113284Q40150325-B12F58D7-CDD7-4339-857C-D1BA3618D963Q46665043-2419B47A-6D69-41E2-BF4D-E84D82416CBDQ47554771-E8F413DF-FF73-4425-BA0F-C77B2E23E44AQ53246833-842257F7-F16A-4780-84CD-88DE6698E29DQ57572364-104F8733-6C1A-4B9D-AB11-FFC4C1D8BD59Q57846534-5C3004FF-82BF-47F7-BBF8-75F7EDAC4DFD
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Genetic testing for cancer predisposition.
@ast
Genetic testing for cancer predisposition.
@en
Genetic testing for cancer predisposition.
@nl
type
label
Genetic testing for cancer predisposition.
@ast
Genetic testing for cancer predisposition.
@en
Genetic testing for cancer predisposition.
@nl
prefLabel
Genetic testing for cancer predisposition.
@ast
Genetic testing for cancer predisposition.
@en
Genetic testing for cancer predisposition.
@nl
P2093
P1476
Genetic testing for cancer predisposition.
@en
P2093
P304
P356
10.1146/ANNUREV.MED.52.1.371
P577
2001-01-01T00:00:00Z